Companies in #Bispecific Antibodies

FUJIFILM Biotechnologies is a global contract development and manufacturing organization (CDMO) focused on biologics, gene therapies, and vaccines, and is the second-largest biologics CDMO globally by capacity. The company operates as a subsidiary of FUJIFILM Holdings Corporation (Tokyo Stock Exchange: 4901) and provides end-to-end services from cell line development through commercial-scale manufacturing for mammalian cell culture, microbial fermentation, and viral vector production. FUJIFILM Biotechnologies has executed $6.2B+ in global capacity expansion in recent years, including flagship facilities in Hillerød, Denmark (acquired from Biogen in 2019) and Holly Springs, North Carolina, USA (a $3.2B commercial-scale cell-culture biomanufacturing site that opened in 2025-2026). The Holly Springs site was selected in June 2026 for the FDA PreCheck Pilot Program, validating its commercial-scale biologics manufacturing capacity for US drug supply.

OmniAb licenses antibody discovery technology to pharmaceutical, biotech, and academic partners, using engineered transgenic animals (OmniRat, OmniChicken, OmniMouse), bispecific platforms (OmniFlic, OmniClic), cow-inspired OmniTaur antibodies, the OmnidAb single-domain platform, and the OmniDeep suite of in-silico AI/ML discovery tools. Spun out of Ligand Pharmaceuticals in 2022 and headquartered in Emeryville, California, the company generates revenue through partnered milestone payments and license fees; Q2 2026 revenue more than tripled year over year as partner milestones accelerated, and it raised its full-year 2026 revenue and year-end cash outlook.

Zymeworks is a clinical-stage biotechnology company developing multifunctional biotherapeutics for difficult-to-treat cancers. The company's platforms include Azymetric (bispecific antibodies) and EFECT (immune-effector modulation), and it is advancing multiple wholly-owned and partnered oncology candidates. In 2026 Zymeworks expanded its pipeline through the near-$1B acquisition of Theravance Biopharma, adding a lung-disease drug candidate plus royalty streams.